Summary table outlining the workup performed to rule out underlying thrombotic disorders
| Test | One-time tests | On admission | On discharge | On readmission |
| COVID-19 (Rapid Abbott) | – | Negative | – | Negative |
| Prothrombin Time (PT) (s) | – | 12.2 | – | – |
| Activated Partial Thromboplastin Time (aPTT) (s) | – | 26.4 | – | – |
| International Normalized Ratio (INR) | – | 1.13 | – | – |
| Fibrinogen (mg/dL) | – | 142 | – | – |
| Platelets (×103/μL) | – | 21 | 132 | 168 |
| Slide review | – | Decreased platelet sufficiency | Decreased platelet sufficiency | – |
| D-dimer (mg/L) | – | >35.20 | – | – |
| White Blood Cell Count (WBC) (×103/μL) | – | 7.14 | 5.77 | 6.14 |
| Rheumatoid factor (IU/mL) | 9 | – | – | – |
| Anti-DS DNA | Negative | – | – | – |
| Anti-Smith antibody | Negative | – | – | – |
| Cardiolipin IgA/G/M (U/mL) | 0.7/<1.6/1.8 | – | – | – |
| Factor V Leiden mutation | Negative | – | – | – |
| Peripheral smear | Thrombocytopenia with high mean platelet volume (MPV) | – | – | – |
| Lactate Dehydrogenase (LDH) (U/L) | – | 233 | – | – |
| Indirect Coombs | Negative | – | – | – |
| Blood type ABO/Rh | O positive | – | – | – |
| anti-nuclear antibody (ANA) | Positive | – | – | – |
| Prothrombin factor II 20210G>A mutation | Negative | – | – | – |
| Antithrombin III activity | 143 % | – | – | – |
| Antithrombin III antigen | 113% | – | – | – |
| Protein C activity | 113% | – | – | – |
| Protein C antigen | 117% | – | – | – |
| Protein S activity | 88% | – | – | – |
| Protein S antigen | 113% | – | – | – |
| Hexagonal phospholipids | Negative | – | – | – |
| Heparin induced platelet Ab (HIT) (PF4 Ab) (Units-OD) | 2.702 | – | – | – |
| Platelet Ab direct flow cytometry | Negative | – | – | – |
| Factor VIII antigen | 180% | – | – | – |
| Lupus inhibitor/anticoagulant | Negative, test suggestive of heparin effect | – | – | – |
| Creatinine (mg/dL) | – | 0.8 | 0.8 | 0.87 |
| Troponin I (ng/mL) | – | 0.003 | – | 0.1070 |
PF4, platelet factor 4.